Kura Oncology to Participate in Jefferies Global Healthcare Conference
Kura Oncology, a clinical-stage biopharmaceutical company, has announced its participation in the Jefferies Global Healthcare Conference.
Troy Wilson, President and CEO, will engage in a virtual fireside chat on June 5, 2024, at 3:00 p.m. ET / 12:00 p.m. PT.
A live audio webcast and an archived replay will be accessible in the Investors section of Kura's website.
- Kura Oncology's participation in the Jefferies Global Healthcare Conference increases visibility among investors and industry stakeholders.
- The scheduled virtual fireside chat with the CEO can provide valuable insights and strategic updates to investors.
- There is no new clinical or financial data disclosed in the announcement, which may leave some investors seeking more substantial updates.
- The announcement does not mention any forthcoming product developments or milestones, potentially indicating a lack of imminent breakthroughs.
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Jefferies Global Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 3:00 p.m. ET / 12:00 p.m. PT on June 5, 2024. A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay following the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in NPM1-mutant R/R AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in NPM1-mutant and KMT2A-rearranged newly diagnosed and R/R AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent HNSCC (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors:
Pete De Spain
Executive Vice President, Investor Relations &
Corporate Communications
(858) 500-8833
pete@kuraoncology.com
Media:
Alexandra Weingarten
Associate Director, Corporate Communications &
Investor Relations
(858) 500-8822
alexandra@kuraoncology.com
FAQ
When will Kura Oncology participate in the Jefferies Global Healthcare Conference?
What time is the Kura Oncology fireside chat at the Jefferies Global Healthcare Conference?
Who will represent Kura Oncology at the Jefferies Global Healthcare Conference?
How can I access the Kura Oncology fireside chat at the Jefferies Global Healthcare Conference?
